Thomas A. Puchalski
CSL (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial(2014)424 cited
- → Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer(2012)393 cited
- → Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors(2007)302 cited
- → Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy(2004)292 cited
- → A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors(2013)258 cited
- → Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily(2002)245 cited
- → Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study(2014)208 cited
- → A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors(2014)203 cited
- → A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease(2013)203 cited
- → Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study(2005)191 cited